Tech Center 1600 • Art Units: 1644 1646
This examiner grants 64% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18465854 | COMPOSITIONS AND METHODS OF TREATING LUPUS NEPHRITIS | Non-Final OA | Hoffmann-La Roche Inc. |
| 17754992 | METHODS TO PREPARE V-T CELLS DERIVED EXOSOMES FOR TREATMENT OF EPSTEIN-BARR VIRUS-ASSOCIATED CANCERS | Final Rejection | THE UNIVERSITY OF HONG KONG |
| 18264279 | ANTIBODIES AGAINST CD112R AND USES THEREOF | Non-Final OA | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. |
| 18025879 | METHODS, THERAPIES AND USES FOR TREATING CANCER | Non-Final OA | PFIZER INC. |
| 18306956 | INNATE IMMUNE PROTEINS AS BIOMARKERS FOR TRAUMATIC BRAIN INJURY IN ADULT AND PEDIATRIC PATIENTS | Non-Final OA | University of Miami |
| 17921600 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMASOME RELATED DISEASES OR CONDITIONS | Final Rejection | University of Miami |
| 17240609 | Materials and Methods for Treating Juvenile Idiopathic Arthritis | Final Rejection | Janssen Biotech, Inc. |
| 17312855 | Models and Methods Useful for the Treatment of Serrated Colorectal Cancer | Non-Final OA | Sanford Burnham Prebys Medical Discovery Institute |
| 17286247 | METHOD FOR THE TREATMENT OF MYASTHENIA GRAVIS | Final Rejection | UCB BIOPHARMA SRL |
| 17855474 | ASSESSMENT METHODS AND DIAGNOSTIC KIT FOR PREDICTING ACUTE ANTIDEPRESSANT RESPONSE AND REMISSION IN PATIENTS WITH DEPRESSIVE DISORDERS USING MULTIMODAL SERUM BIOMARKERS | Non-Final OA | INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY |
| 18551851 | CYSTEINE ENGINEERED ANTIBODY CONSTRUCTS, CONJUGATES AND METHODS OF USE | Non-Final OA | ZYMEWORKS INC. |
| 18260905 | ROR1-TARGETING ANTIBODY AND USE THEREOF | Non-Final OA | BIOHENG THERAPEUTICS LIMITED |
| 18324105 | GENETICALLY ENGINEERED DENDRITIC CELLS TO ACTIVATE PROTEIN SPECIFIC T CELLS FOR THE TREATMENT OF VIRAL AND OTHER PATHOGENIC INFECTIONS | Non-Final OA | NeyroblastGX LLC, |
| 18028917 | ANTI-ADENOSINE RECEPTOR (A2aR) ANTIBODIES | Non-Final OA | Adept Biopharmaceutical and Technology, Ltd. |
| 16586730 | METHODS FOR IDENTIFYING ACTIVATING ANTIGEN RECEPTOR (aCAR)/INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR) PAIRS FOR USE IN CANCER THERAPIES | Non-Final OA | GAVISH-GALILEE BIO APPLICATIONS LTD. |
| 17789940 | Epithelial Cadherin-Specific Antibodies | Final Rejection | Kling Biotherapeutics B.V. |
| 17616575 | BISPECIFIC BINDING CONSTRUCTS WITH SELECTIVELY CLEAVABLE LINKERS | Final Rejection | AMGEN RESEARCH (MUNICH) GMBH |
| 17368815 | USE OF AN ANTI-CD45 ANTIBODY DRUG CONJUGATE (ADC) IN CELL THERAPY | Final Rejection | Magenta Therapeutics, Inc. |
| 17593408 | COMBINATION THERAPY WITH OMOMYC AND AN ANTIBODY BINDING PD-1 OR CTLA-4 FOR THE TREATMENT OF CANCER | Final Rejection | PEPTOMYC, S.L. |
| 17309955 | CONSTRUCTS TARGETING LABYRINTHIN OR A PORTION THEREOF AND USES THEREOF | Non-Final OA | LabyRx Immunologic Therapeutics (USA) Limited |
| 17053525 | GYCOMODULE MOTIFS AND USES THEREOF | Non-Final OA | GAT BIOSCIENCES, S.L. |
| 17050988 | COMPOSITIONS AND METHODS RELATING TO THE TREATMENT OF DISEASES | Final Rejection | ILC Therapeutics LTD |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy